



(86) **Date de dépôt PCT/PCT Filing Date:** 2009/04/28  
 (87) **Date publication PCT/PCT Publication Date:** 2009/11/05  
 (45) **Date de délivrance/Issue Date:** 2019/03/19  
 (85) **Entrée phase nationale/National Entry:** 2010/10/21  
 (86) **N° demande PCT/PCT Application No.:** US 2009/041981  
 (87) **N° publication PCT/PCT Publication No.:** 2009/134805  
 (30) **Priorité/Priority:** 2008/04/28 (US61/048,522)

(51) **Cl.Int./Int.Cl. C07K 16/24** (2006.01),  
**A61K 39/395** (2006.01), **A61P 11/00** (2006.01),  
**A61P 19/00** (2006.01), **A61P 9/00** (2006.01)

(72) **Inventeurs/Inventors:**  
 BEBBINGTON, CHRISTOPHER R., US;  
 LUEHRSEN, KENNETH, US;  
 YARRANTON, GEOFFREY T., US

(73) **Propriétaire/Owner:**  
 KALOBIOS PHARMACEUTICALS, INC., US

(74) **Agent:** NORTON ROSE FULBRIGHT CANADA  
 LLP/S.E.N.C.R.L., S.R.L.

(54) **Titre : ANTICORPS DU FACTEUR DE STIMULATION DE COLONIES DE MACROPHAGES ET DE GRANULOCYTES**  
 (54) **Title: ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR**

VH1 1-02 QVQLVQSGAEVKPGASVKVSKASGYTFTGYYMHVVRQAPCQGLEWMGWINPNSGGTNYAQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----  
 VH#1 QVQLVQSGAEVKPGASVKVSKASGYTFTGYYMHVVRQAPCQGLEWMGWINPNSGGTNYAQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----

VH1 1-03 QVQLVQSGAEVKPGASVKVSKASGYTFTSYAMEHVRQAPCQGLEWMGWINAGNGNTKYSQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----  
 VH#2 QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHHVVRQAPCQGLEWMGWINAGNGNTKYSQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----  
 VH#3 QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHHVVRQAPCQGLEWMGWINAGNGNTKYSQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----  
 VH#4 QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHHVVRQAPCQGLEWMGWINAGNGNTKYSQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----  
 VH#5 QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHHVVRQAPCQGLEWMGWINAGNGNTKYSQKFQGRVITMTRDTSISTAYMELSLRSLRSDDTAVYYCAR-----

VKIII A27 EIVLTOQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGIDFTLTISRLSPEDFAVYYCQQYQSSP-----  
 VK#1 EIVLTOQSPATLSVSPGERATLSCRASQSVGTN-VANYQQKPGQAPRVLIVIYSTSSRATGITDRFSGSGSGTDFTLTISRLSPEDFAVYYCQQQFNRSPLTFGGGTKVBIK  
 VK#2 EIVLTOQSPATLSVSPGERATLSCRASQSVGTN-VANYQQKPGQAPRVLIVIYSTSSRATGITDRFSGSGSGTDFTLTISRLSPEDFAVYYCQQQFNRSPLTFGGGTKVBIK  
 VK#3 EIVLTOQSPATLSVSPGERATLSCRASQSIGSN-LAWYQQKPGQAPRVLIVIYSTSSRATGITDRFSGSGSGTDFTLTISRLSPEDFAVYYCQQQFNRSPLTFGGGTKVBIK  
 VK#4 EIVLTOQSPATLSVSPGERATLSCRASQSIGSN-LAWYQQKPGQAPRVLIVIYSTSSRATGITDRFSGSGSGTDFTLTISRLSPEDFAVYYCQQQFNRSPLTFGGGTKVBIK

Fab	Vh	Vk	Dissociation rate for binding to GM-CSF determined by surface plasmon resonance analysis (s <sup>-1</sup> )
FB42-8	#2	#3	$1.36 \times 10^{-4}$
FB44-5	#1	#3	$8.0 \times 10^{-5}$
FB77-2	#3	#1	$5.57 \times 10^{-5}$
FB92-1	#4	#4	$3.84 \times 10^{-5}$
FB94-1	#4	#2	$3.12 \times 10^{-5}$
FB104-1	#5	#1	$3.57 \times 10^{-5}$
FB106-1	#5	#2	$5.4 \times 10^{-5}$

**(57) Abrégé/Abstract:**

The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 November 2009 (05.11.2009)(10) International Publication Number  
WO 2009/134805 A3(51) International Patent Classification:  
C07K 16/22 (2006.01) C12P 21/08 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:  
PCT/US2009/041981(22) International Filing Date:  
28 April 2009 (28.04.2009)(25) Filing Language:  
English(26) Publication Language:  
English(30) Priority Data:  
61/048,522 28 April 2008 (28.04.2008) US

(71) Applicant (for all designated States except US): KALO-BIOS PHARMACEUTICALS, INC. [US/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEBBINGTON, Christopher, R. [GB/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US). LUEHRSEN, Kenneth [US/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US). YARRANTON, Geoffrey, T. [GB/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US).

(74) Agents: LOCKYER, Jean, M. et al.; Townsend And Townsend And Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:  
3 June 2010

(54) Title: ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

FIGURE 1

VH1 1-02 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVR-----  
VH#1 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVRQKRPFPYDWQGQTLVTVSS

VH1 1-03 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVR-----  
VH#2 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVRQKRPFPYDWQGQTLVTVSS

VH#3 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVRQKRPFPYDWQGQTLVTVSS

VH#4 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVRQKRPFPYDWQGQTLVTVSS

VH#5 QVQLVQSGAEVYKPGASVVKVSCASGYYPQGQLEWNGMWHNRSQGTYVQKPFQSRVNTNTRDTS1STAYMELSLRSLSEDATAVYYCVRQKRPFPYDWQGQTLVTVSS

VK111 A27 EIVLQSPATLSVSPGERATLSCRASOIGN-LANVYQKQDQANRVRVLYSTSSRATQ11949G66K97DFTL015RLETRDPAVYYCQPNKREPLITP3337KVEIK  
VK#1 EIVLQSPATLSVSPGERATLSCRASOIGN-LANVYQKQDQANRVRVLYSTSSRATQ11949G66K97DFTL015RLETRDPAVYYCQPNKREPLITP3337KVEIK  
VK#2 EIVLQSPATLSVSPGERATLSCRASOIGN-LANVYQKQDQANRVRVLYSTSSRATQ11949G66K97DFTL015RLETRDPAVYYCQPNKREPLITP3337KVEIK  
VK#3 EIVLQSPATLSVSPGERATLSCRASOIGN-LANVYQKQDQANRVRVLYSTSSRATQ11949G66K97DFTL015RLETRDPAVYYCQPNKREPLITP3337KVEIK  
VK#4 EIVLQSPATLSVSPGERATLSCRASOIGN-LANVYQKQDQANRVRVLYSTSSRATQ11949G66K97DFTL015RLETRDPAVYYCQPNKREPLITP3337KVEIK

Fab	Vh	Vk	Dissociation rate for binding to GM-CSF determined by surface plasmon resonance analysis (s <sup>-1</sup> )
FB42-8	#2	#3	1.36 x 10 <sup>-3</sup>
FB44-5	#1	#3	8.0 x 10 <sup>-5</sup>
FB77-2	#3	#1	5.57 x 10 <sup>-5</sup>
FB92-1	#4	#4	3.84 x 10 <sup>-5</sup>
FB94-1	#4	#2	3.12 x 10 <sup>-5</sup>
FB104-1	#5	#1	3.57 x 10 <sup>-5</sup>
FB106-1	#5	#2	5.4 x 10 <sup>-5</sup>

(57) Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

## Antibodies to Granulocyte-Macrophage Colony-Stimulating Factor

### BACKGROUND

[0001] "Granulocyte Macrophage-Colony Stimulating Factor" (GM-CSF) is a small glycoprotein that is produced in response to a number of inflammatory mediators by cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages and inhibits apoptosis of granulocytes and macrophages.

[0002] GM-CSF has been proposed to play a role in the pathogenesis of a number of diseases. There is therefore a need for additional therapies that target GM-CSF.

15

### BRIEF SUMMARY

[0003] In one aspect, this disclosure provides anti-GM-CSF antibodies, *e.g.*, humanized antibodies, and methods of using such antibodies for the treatment of diseases for which it is desirable to inhibit GM-CSF receptor signaling. Thus, in some embodiments, this disclosure provides an anti-GM-CSF antibody, comprising a heavy chain variable region that comprises a CDR3 binding specificity determinant RQRFPY (SEQ ID NO:12) or RDRFPY (SEQ ID NO:13), a J segment, and a V-segment, wherein the J-segment comprises at least 95% identity to human JH4 (YFDYWGQGTLTVSS; SEQ ID NO:14) and the V-segment comprises at least 90% identity to a human germ line VH1 1-02 or VH1 1-03 sequence; or a heavy chain variable region that comprises a CDR3 binding specificity determinant comprising RQRFPY (SEQ ID NO:12). In some embodiments, the J segment comprises YFDYWGQGTLTVSS (SEQ ID NO:14). In some embodiments, the CDR3 comprises RQRFPYYFDY (SEQ ID NO:15) or RDRFPYYFDY (SEQ ID NO:16). In some embodiments, the heavy chain variable region CDR1 or CDR2 can be a human germline VH1 sequence; or both the CDR1 and CDR2 can be human germline VH1. In some embodiments, the antibody comprises a heavy chain variable region CDR1 or CDR2, or both CDR1 and CDR2, as shown in a V<sub>H</sub> region set forth in Figure 1. In some embodiments, such an antibody has a V-segment that has a V<sub>H</sub> V-segment sequence

shown in Figure 1. In some embodiments, such an antibody comprises a  $V_H$  that has the sequence of VH#1, VH#2, VH#3, VH#4, or VH#5 set forth in Figure 1.

[0004] This disclosure also provides an anti-GM-CSF antibody, *e.g.*, that has a heavy chain variable region as described in the paragraph above, where the antibody comprises a light chain variable region that comprises a CDR3 binding specificity determinant FNK or FNR. In some embodiments, such an antibody comprises a human germline JK4 region. In some embodiments, the antibody  $V_L$  region CDR3 comprises QQFN(K/R)SPLT (SEQ ID NO:17), *e.g.*, QQFNKSPLT (SEQ ID NO:18). In some embodiments, the light chain variable region comprises a CDR1, or a CDR2, or both a CDR1 and CDR2, of a  $V_L$  region shown in Figure 1.

10 In some embodiments, the  $V_L$  region comprises a V segment that has at least 95% identity to the VKIIIA27 V-segment sequence as shown in Figure 1. In some embodiments, the  $V_L$  region has the sequence of VK#1, VK#2, VK#3, or VK#4 set forth in Figure 1.

[0005] In some embodiments, an antibody as disclosed herein, *e.g.*, that has a  $V_H$  region sequence selected from the  $V_H$  region sequences in Figure 1 and a  $V_L$  region selected from the  $V_L$  region sequences in Figure 1, have a monovalent affinity better than about 10 nM, and often better (less) than about 500 pM or better than about 50 pM as determined by surface plasmon resonance analysis performed at 37°C. Thus, in some embodiments, such antibodies have an affinity (as measured using surface plasmon resonance), of less than 50 pM, typically less than about 25 pM, or even less than 10 pM. In some embodiments, an anti-GM-CSF has a slow dissociation rate with a dissociation rate constant (kd) determined by surface plasmon resonance analysis at 37°C for the monovalent interaction with GM-CSF less than approximately  $10^{-4} \text{ s}^{-1}$ , preferably less than  $5 \times 10^{-5} \text{ s}^{-1}$  and most preferably less than  $10^{-5} \text{ s}^{-1}$ . In some embodiments, such an antibody has a dissociation rate that is at least 2 to 3-fold slower than a reference chimeric c19/2 monoclonal antibody assayed under the same conditions, but has a potency that is at least 6-10 times greater than that of the reference antibody in neutralizing GM-CSF activity in a cell-based assay that measures GM-CSF activity.

20

25

[0006] In some embodiments, an antibody as disclosed herein having a heavy chain variable region and/or a light chain variable region as described herein is an IgG. In some embodiments, the heavy chain has a constant region that has the amino acid sequence of SEQ ID NO:11. In some embodiments, the light chain constant region is a kappa light chain having a sequence set forth in SEQ ID NO:10. In some embodiments, such an antibody has a heavy chain constant

region as set forth in SEQ ID NO:11, a light chain kappa constant region having a sequence as set forth in SEQ ID NO:10 and a heavy chain and light chain variable region selected from the heavy and light chain variable regions shown in Figure 1, *e.g.*, the antibody heavy and light chain variable regions comprise one of the following combinations from the sequences set forth in Figure 1: a)

5 VH#2, VK#3; b) VH#1, VK#3; c) VH#3, VK#1; d) VH#4, VK#3; e) VH#4, VK#4; f) VH#4, VK#2; g) VH#5, VK#1; h) VH#5, VK#2; i) VH#3, VK#4; or j) VH#3, VL#3). One of skill will recognize that such antibodies can be selected from any of the combinations of  $V_H$  and  $V_L$  regions set forth in Figure 1 in conjunction with the teachings herein.

10 [0007] In some embodiments, the  $V_H$  region sequence or  $V_L$  region sequence, or both the  $V_H$  and  $V_L$  region amino acid sequences, comprise a methionine at the N-terminus.

15 [0008] In additional aspects, this disclosure provides a method of treating a patient that has a disease in which it is desirable to inhibit GM-CSF, the method comprising administering an antibody to the patient in a therapeutically effective amount. In some embodiments, the patient has osteopenia, rheumatoid arthritis, asthma, multiple sclerosis, psoriasis, chronic obstructive pulmonary disease, idiopathic thrombocytopenia purpura, Alzheimer's disease, heart failure, cardiac damage due to an ischemic event, or diabetes.

20 [0009] The claimed invention relates to an anti-GM-CSF antibody, comprising: (a) a  $V_H$  region that comprises a CDR3 having a sequence RQRFPYYFDY (SEQ ID NO:15); a CDR1 having a sequence NYYIH (SEQ ID NO:25); and a CDR2 having a sequence WINAGNGNTKYSQKFQG (SEQ ID NO:27); and a  $V_L$  region that comprises a CDR3 having a sequence QQFN(K/R)SPLT (SEQ ID NO:17); a CDR1 having a sequence RASQSVGTNVA (SEQ ID NO:31) or RASQSIGSNLA (SEQ ID NO:32); and a CDR2 having a sequence STSSRAT (SEQ ID NO:33). In some embodiments, the  $V_L$  region comprises the CDR3 sequence QQFNKSPLT (SEQ ID NO:18), the CDR1 sequence RASQSVGTNVA (SEQ ID NO:31), and the CDR2 sequence STSSRAT (SEQ ID NO:33). In some 25 embodiments, the  $V_H$  region FR4 sequence is WGQGTLVTVSS. In some embodiments, the antibody has a heavy chain variable region sequence and a light chain variable region sequence selected from the group consisting of: (a) VH#3 (SEQ ID NO:3) and VK#1 (SEQ ID NO:6); (b) VH#4 (SEQ ID NO:4) and VK#4 (SEQ ID NO:9); (c) VH#4 (SEQ ID NO:4) and VK#2 (SEQ ID NO:7); and (d) VH#5 (SEQ ID NO:5) and VK#1 (SEQ ID NO:6). In some embodiments, the 30 antibody is an IgG. Also claimed is a pharmaceutical composition comprising such an antibody and a physiologically acceptable carrier. Such an antibody or composition can be used for binding GM-CSF and may be for use in inhibiting GM-CSF receptor activation for therapeutic purposes as described herein.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 provides exemplary  $V_H$  (SEQ ID NOS:2-5) and  $V_L$  (SEQ ID NOS:6-9) sequences of anti-GM-CSF antibodies. VH1 1-02 = SEQ ID NO:19; VH1 1-03 = SEQ ID NO:20; VKIII A27 = SEQ ID NO:21.

[0011] Figure 2. Binding of GM-CSF to Ab1 (A) or Ab2 (B) determined by surface plasmon resonance analysis at 37°C (Biacore 3000). Ab1 and Ab2 were captured on anti Fab polyclonal antibodies immobilized on the Biacore chip. Different concentrations of GM-CSF were injected over the surface as indicated. Global fit analysis was carried out assuming a 1:1 interaction 10 using Scrubber2 software.

[0012] Figure 3. Binding of Ab1 and Ab2 to glycosylated and non-glycosylated GM-CSF. Binding to glycosylated GM-CSF expressed from human 293 cells or non-glycosylated GM-

CSF expressed in *E. coli* was determined by ELISA. Representative results from a single experiment are shown (exp 1). Two-fold dilutions of Ab1 and Ab2 starting from 1500ng/ml were applied to GM-CSF coated wells. Each point represents mean  $\pm$  standard error for triplicate determinations. Sigmoidal curve fit was performed using Prism 5.0 Software (Graphpad).

5 [0013] Figure 4. Competition ELISA demonstrating binding of Ab1 and Ab2 to a shared epitope. ELISA plates coated with 50 ng/well of recombinant GM-CSF were incubated with various concentrations of antibody (Ab2, Ab1 or isotype control antibody) together with 50nM biotinylated Ab2. Biotinylated antibody binding was assayed using neutravidin-HRP conjugate. Competition for binding to GM-CSF was for 1hr (A) or for 18 hrs (B). Each 10 point represents mean  $\pm$  standard error for triplicate determinations. Sigmoidal curve fit was performed using Prism 5.0 Software (Graphpad).

15 [0014] Figure 5. Inhibition of GM-CSF-induced IL-8 expression. Various amounts of each antibody were incubated with 0.5ng/ml GM-CSF and incubated with U937 cells for 16 hrs. IL-8 secreted into the culture supernatant was determined by ELISA

#### DETAILED DESCRIPTION OF THE INVENTION

20 [0015] As used herein, an "antibody" refers to a protein functionally defined as a binding protein and structurally defined as comprising an amino acid sequence that is recognized by one of skill as being derived from the framework region of an immunoglobulin-encoding gene of an animal that produces antibodies. An antibody can consist of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad 25 immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

30 [0016] A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily

responsible for antigen recognition. The terms variable light chain ( $V_L$ ) and variable heavy chain ( $V_H$ ) refer to these light and heavy chains, respectively.

[0017] The term "antibody" as used herein also includes antibody fragments that retain binding specificity. For example, there are a number of well characterized antibody fragments. Thus, for example, pepsin digests an antibody C-terminal to the disulfide linkages in the hinge region to produce  $F(ab')2$ , a dimer of Fab which itself is a light chain joined to  $VH-CH1$  by a disulfide bond. The  $F(ab')2$  may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the  $(Fab')2$  dimer into a  $Fab'$  monomer. The  $Fab'$  monomer is essentially an Fab with part of the hinge region (see, 10 Fundamental Immunology, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that fragments can be synthesized *de novo* by utilizing recombinant DNA methodology or chemically. Thus, the term "antibody", as used here includes antibody fragments either produced by the 15 modification of whole antibodies or synthesized using recombinant DNA methodologies.

[0018] Antibodies as used here also include various  $V_H-V_L$  pair formats, including single chain antibodies (antibodies that exist as a single polypeptide chain), *e.g.*, single chain Fv antibodies (sFv or scFv), in which a variable heavy and a variable light region are joined together (directly or through a peptide linker) to form a continuous polypeptide. The single 20 chain Fv antibody is a covalently linked  $V_H-V_L$  that may be expressed from a nucleic acid including  $V_H$ - and  $V_L$ - encoding sequences either joined directly or joined by a peptide-encoding linker (*e.g.*, Huston, *et al. Proc. Nat. Acad. Sci. USA*, 85:5879-5883, 1988). While the  $V_H$  and  $V_L$  are connected to each as a single polypeptide chain, the  $V_H$  and  $V_L$  domains associate non-covalently. An antibody can also be in another fragment form, such as a 25 disulfide-stabilized Fv (dsFv). Other fragments can also be generated, *e.g.*, using recombinant techniques, as soluble proteins or as fragments obtained from display methods. Antibodies can also include dianitibodies and miniantibodies.

[0019] Antibodies of the invention also include heavy chain dimers, such as antibodies from camelids. Since the  $V_H$  region of a heavy chain dimer IgG in a camelid does not have to 30 make hydrophobic interactions with a light chain, the region in the heavy chain that normally contacts a light chain is changed to hydrophilic amino acid residues in a camelid.  $V_H$  domains of heavy-chain dimer IgGs are called VHH domains. Antibodies for use in the current

invention additionally include single domain antibodies (dAbs) and nanobodies (*see, e.g.*, Cortez-Retamozo, *et al.*, *Cancer Res.* 64:2853-2857, 2004).

[0020] As used herein, "V-region" refers to an antibody variable region domain comprising the segments of Framework 1, CDR1, Framework 2, CDR2, and Framework 3, including 5 CDR3 and Framework 4, which segments are added to the V-segment as a consequence of rearrangement of the heavy chain and light chain V-region genes during B-cell differentiation. A "V-segment" as used herein refers to the region of the V-region (heavy or light chain) that is encoded by a V gene. The V-segment of the heavy chain variable region encodes FR1-CDR1-FR2-CDR2 and FR3. For the purposes of this invention, the V-segment 10 of the light chain variable region is defined as extending though FR3 up to CDR3.

[0021] As used herein, the term "J-segment" refers to a subsequence of the variable region encoded comprising a C-terminal portion of a CDR3 and the FR4. An endogenous J-segment is encoded by an immunoglobulin J-gene.

[0022] As used herein, "complementarity-determining region (CDR)" refers to the three 15 hypervariable regions in each chain that interrupt the four "framework" regions established by the light and heavy chain variable regions. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, for example, a 20 V<sub>H</sub> CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a V<sub>L</sub> CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found.

[0023] The sequences of the framework regions of different light or heavy chains are 25 relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space.

[0024] The amino acid sequences of the CDRs and framework regions can be determined 30 using various well known definitions in the art, *e.g.*, Kabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (*see, e.g.*, Johnson *et al.*, *supra*; Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. *J. Mol. Biol.* 196, 901-917; Chothia C. *et al.*, 1989, Conformations of immunoglobulin hypervariable regions. *Nature* 342, 877-883; Chothia C. *et al.*, 1992, structural repertoire of the human VH

segments J. Mol. Biol. 227, 799-817; Al-Lazikani *et al.*, *J.Mol.Biol* 1997, 273(4)).

Definitions of antigen combining sites are also described in the following: Ruiz *et al.*, IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.*, 28, 219-221 (2000); and Lefranc,M.-P. IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.* Jan

5 1;29(1):207-9 (2001); MacCallum *et al*, Antibody-antigen interactions: Contact analysis and binding site topography, *J. Mol. Biol.*, 262 (5), 732-745 (1996); and Martin *et al*, *Proc. Natl Acad. Sci. USA*, 86, 9268-9272 (1989); Martin, *et al*, *Methods Enzymol.*, 203, 121-153, (1991); Pedersen *et al*, *Immunomethods*, 1, 126, (1992); and Rees *et al*, In Sternberg M.J.E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996).

10 [0025] "Epitope" or "antigenic determinant" refers to a site on an antigen to which an antibody binds. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed (1996).

20 [0026] The term "binding specificity determinant" or "BSD" as used in the context of the current invention refers to the minimum contiguous or non-contiguous amino acid sequence within a CDR region necessary for determining the binding specificity of an antibody. In the current invention, the minimum binding specificity determinants reside within a portion or the full-length of the CDR3 sequences of the heavy and light chains of the antibody.

25 [0027] As used herein, "anti-GM-CSF antibody" or "GM-CSF antibody" are used interchangeably to refer to an antibody that binds to GM-CSF and inhibits GM-CSF receptor activity. Such antibodies may be identified using any number of art-recognized assays that assess GM-CSF binding and/or function. For example, binding assays such as ELISA assays that measure the inhibition of GM-CSF binding to the alpha receptor subunit may be used.

30 Cell-based assays for GM-CSF receptor signaling, such as assays which determine the rate of proliferation of a GM-CSF-dependent cell line in response to a limiting amount of GM-CSF,

are also conveniently employed, as are assays that measure amounts of cytokine production, *e.g.*, IL-8 production, in response to GM-CSF exposure.

[0028] As used herein, "neutralizing antibody" refers to an antibody that binds to GM-CSF and inhibits signaling by the GM-CSF receptor, or inhibits binding of GM-CSF to its  
5 receptor.

[0029] As used herein, "Granulocyte Macrophage-Colony Stimulating Factor" (GM-CSF) refers to a small naturally occurring glycoprotein with internal disulfide bonds having a molecular weight of approximately 23 kDa. In humans, it is encoded by a gene located within the cytokine cluster on human chromosome 5. The sequence of the human gene and  
10 protein are known. The protein has an N-terminal signal sequence, and a C-terminal receptor binding domain (Rasko and Gough In: The Cytokine Handbook, A. Thomson, *et al*, Academic Press, New York (1994) pages 349-369). Its three-dimensional structure is similar to that of the interleukins, although the amino acid sequences are not similar. GM-CSF is produced in response to a number of inflammatory mediators present in the hemopoietic  
15 environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages and inhibits apoptosis of granulocytes and macrophages.

[0030] The term "equilibrium dissociation constant" or "affinity" abbreviated ( $K_D$ ), refers to the dissociation rate constant ( $k_d$ ,  $\text{time}^{-1}$ ) divided by the association rate constant ( $k_a$ ,  $\text{time}^{-1}$   $\text{M}^{-1}$ ). Equilibrium dissociation constants can be measured using any known method in the art. The antibodies of the present invention are high affinity antibodies. Such antibodies have a monovalent affinity better (less) than about 10 nM, and often better than about 500  
20 pM or better than about 50 pM as determined by surface plasmon resonance analysis performed at 37°C. Thus, in some embodiments, the antibodies of the invention have an affinity (as measured using surface plasmon resonance), of less than 50 pM, typically less than about 25 pM, or even less than 10 pM.

[0031] In some embodiments, an anti-GM-CSF of the invention has a slow dissociation rate  
30 with a dissociation rate constant ( $k_d$ ) determined by surface plasmon resonance analysis at 37°C for the monovalent interaction with GM-CSF less than approximately  $10^{-4} \text{ s}^{-1}$ , preferably less than  $5 \times 10^{-5} \text{ s}^{-1}$  and most preferably less than  $10^{-5} \text{ s}^{-1}$ .

[0032] As used herein, "humanized antibody" refers to an immunoglobulin molecule in CDRs from a donor antibody are grafted onto human framework sequences. Humanized antibodies may also comprise residues of donor origin in the framework sequences. The humanized antibody can also comprise at least a portion of a human immunoglobulin 5 constant region. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Humanization can be performed using methods known in the art (e.g., Jones *et al.*, *Nature* 321:522-525; 1986; Riechmann *et al.*, *Nature* 332:323-327, 1988; Verhoeven *et al.*, *Science* 239:1534-1536, 1988); Presta, *Curr. Op. Struct. Biol.* 2:593-596, 1992; U.S. Patent No. 4,816,567), 10 including techniques such as "superhumanizing" antibodies (Tan *et al.*, *J. Immunol.* 169: 1119, 2002) and "resurfacing" (e.g., Staelens *et al.*, *Mol. Immunol.* 43: 1243, 2006; and Roguska *et al.*, *Proc. Natl. Acad. Sci USA* 91: 969, 1994).

[0033] A "humaneered" antibody in the context of this invention refers to an engineered 15 human antibody having a binding specificity of a reference antibody. A "humaneered" antibody for use in this invention has an immunoglobulin molecule that contains minimal sequence derived from a donor immunoglobulin. Typically, an antibody is "humaneered" by joining a DNA sequence encoding a binding specificity determinant (BSD) from the CDR3 region of the heavy chain of the reference antibody to human V<sub>H</sub> segment sequence and a light chain CDR3 BSD from the reference antibody to a human V<sub>L</sub> segment sequence. A 20 "BSD" refers to a CDR3-FR4 region, or a portion of this region that mediates binding specificity. A binding specificity determinant therefore can be a CDR3-FR4, a CDR3, a minimal essential binding specificity determinant of a CDR3 (which refers to any region smaller than the CDR3 that confers binding specificity when present in the V region of an antibody), the D segment (with regard to a heavy chain region), or other regions of CDR3- 25 FR4 that confer the binding specificity of a reference antibody. Methods for humaneering are provided in US patent application publication no. 20050255552 and US patent application publication no. 20060134098.

[0034] A "human" antibody as used herein encompasses humanized and humaneered 30 antibodies, as well as human monoclonal antibodies that are obtained using known techniques.

[0035] The term "hybrid" when used with reference to portions of a nucleic acid or protein, indicates that the nucleic acid or protein comprises two or more subsequences that are not

normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid. Similarly, a hybrid protein refers to two or more subsequences that are not normally found in the same relationship to each other in nature.

5 [0036] The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant 10 cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, 15 operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the in vivo cellular machinery of the 20 host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a “recombinant protein” is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

25 [0037] The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction where the antibody binds to the protein of interest. In the context of this invention, the antibody binds to the antigen of interest, e.g., GM-CSF, with an affinity that is at least 100-fold better than its affinity for other antigens.

30 [0038] The terms “identical” or percent “identity,” in the context of two or more polypeptide (or nucleic acid) sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues (or nucleotides) that are

the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default 5 parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site). Such sequences are then said to be "substantially identical." "Substantially identical" sequences also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account 10 for gaps and the like. Preferably, protein sequence identity exists over a region that is at least about 25 amino acids in length, or more preferably over a region that is 50-100 amino acids = in length, or over the length of a protein.

[0039] A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 15 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), 20 by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, 25 e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

[0040] Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., *Nuc. Acids Res.* 25:3389-3402 (1977) and Altschul et al., *J. Mol. Biol.* 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described 30 herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E)

of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

**[0041]** The terms “isolated,” “purified,” or “biologically pure” refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. The term “purified” in some embodiments denotes that a protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

**[0042]** The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

**[0043]** The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline,  $\gamma$ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an  $\alpha$  carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

**[0044]** Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

**[0045]** “Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to 5 essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded 10 polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can 15 be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

**[0046]** As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which 20 alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables and substitution matrices such as BLOSUM providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude 25 polymorphic variants, interspecies homologs, and alleles of the invention. Typical conservative substitutions for one another include: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, 30 e.g., Creighton, Proteins (1984)).

## I. Introduction

[0047] The invention relates to antibodies that bind with high affinity to GM-CSF and are antagonists of GM-CSF. The antibodies comprise variable regions with a high degree of identity to human germ-line V<sub>H</sub> and V<sub>L</sub> sequences. In preferred embodiments, the BSD sequence in

5 CDRH3 of an antibody of the invention comprises the amino acid sequence RQRFPY (SEQ ID NO:12) or RDRFPY (SEQ ID NO:13). The BSD in CDRL3 comprises FNK or FNR.

[0048] Complete V-regions are generated in which the BSD forms part of the CDR3 and additional sequences are used to complete the CDR3 and add a FR4 sequence. Typically, the portion of the CDR3 excluding the BSD and the complete FR4 are comprised of human

10 germ-line sequences. In some embodiments, the CDR3-FR4 sequence excluding the BSD differs from human germ-line sequences by not more than 2 amino acids on each chain. In some embodiments, the J-segment comprises a human germline J-segment. Human germline sequences can be determined, for example, through the publicly available international ImMunoGeneTics database (IMGT) and V-base (on the worldwide web at vbase.mrc-cpe.cam.ac.uk).

[0049] The human germline V- segment repertoire consists of 51 heavy chain V-regions, 40 κ light chain V-segments, and 31 λ light chain V-segments, making a total of 3,621 germline V-region pairs. In addition, there are stable allelic variants for most of these V-segments, but the contribution of these variants to the structural diversity of the germline

20 repertoire is limited. The sequences of all human germ-line V-segment genes are known and can be accessed in the V-base database, provided by the MRC Centre for Protein Engineering, Cambridge, United Kingdom (see, also Chothia et al., 1992, J Mol Biol 227:776-798; Tomlinson et al., 1995, EMBO J 14:4628-4638; and Williams et al., 1996, J Mol Biol 264:220-232).

25 [0050] Antibodies or antibodies fragments as described herein can be expressed in prokaryotic or eukaryotic microbial systems or in the cells of higher eukaryotes such as mammalian cells.

[0051] An antibody that is employed in the invention can be in any format. For example, in some embodiments, the antibody can be a complete antibody including a constant region, 30 e.g., a human constant region, or can be a fragment or derivative of a complete antibody, e.g.,

a Fab, Fab', F(ab')<sub>2</sub>, scFv, Fv, or a single domain antibody, such as a nanobody or a camelid antibody.

## II. Heavy Chains

[0052] A heavy chain of an anti-GM-CSF antibody of the invention comprises a heavy-chain

5 V-region that comprises the following elements:

- 1) human heavy-chain V-segment sequences comprising FR1-CDR1-FR2-CDR2-FR3
- 2) a CDRH3 region comprising the amino acid sequence R(Q/D)RFPY (SEQ ID NO:22)
- 3) a FR4 contributed by a human germ-line J-gene segment.

10 Examples of V-segment sequences that support binding to GM-CSF in combination with a CDR3-FR4 segment described above together with a complementary V<sub>L</sub> region are shown in Figure 1. The V-segments can be, e.g., from the human VH1 subclass. In some embodiments, the V-segment is a human V<sub>H</sub>1 sub-class segment that has a high degree of amino-acid sequence identity, e.g., at least 80%, 85%, or 90% or greater identity, to the germ-line segment VH1 1-02  
15 or VH1 1-03. In some embodiments, the V-segment differs by not more than 15 residues from VH1 1-02 or VH1 1-03 and preferably not more than 7 residues.

[0053] The FR4 sequence of the antibodies of the invention is provided by a human JH1, JH3, JH4, JH5 or JH6 gene germline segment, or a sequence that has a high degree of amino-acid sequence identity to a human germline JH segment. In some embodiments, the J segment is a human germline JH4 sequence.

[0054] The CDRH3 also comprises sequences that are derived from a human J-segment.

Typically, the CDRH3-FR4 sequence excluding the BSD differs by not more than 2 amino acids from a human germ-line J-segment. In typical embodiments, the J-segment sequences in CDRH3 are from the same J-segment used for the FR4 sequences. Thus, in some embodiments, the  
25 CDRH3-FR4 region comprises the BSD and a complete human JH4 germ-line gene segment. An exemplary combination of CDRH3 and FR4 sequences is shown below (SEQ ID NO:23), in which the BSD is in bold and human germ-line J-segment JH4 residues are underlined:

CDR3

R (Q/D) RFPYYFDYWGQGTLVTVSS

30

[0055] In some embodiments, an antibody of the invention comprises a V-segment that has at least 90% identity, or at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%

identity to the germ-line segment VH 1-02 or VH1-03; or to one of the V-segments of the  $V_H$  regions shown in Figure 1, such as a V-segment portion of VH#1, VH#2, VH#3, VH#4, or VH#5.

5 [0056] In some embodiments, the V-segment of the  $V_H$  region has a CDR1 and/or CDR2 as shown in Figure 1. For example, an antibody of the invention may have a CDR1 that has the sequence GYYMH (SEQ ID NO:24) or NYYIH (SEQ ID NO:25); or a CDR2 that has the sequence WINPNSGGTNYAQKFQG (SEQ ID NO:26) or WINAGNGNTKYSQKFQG (SEQ ID NO:27).

10 [0057] In particular embodiments, an antibody has both a CDR1 and a CDR2 from one of the  $V_H$  region V-segments shown in Figure 1 and a CDR3 that comprises R(Q/D)RFPY (SEQ ID NO:22), *e.g.*, RDRFPYYFDY (SEQ ID NO:16) or QRFPYYFDY (SEQ ID NO:15). Thus, in some embodiments, an anti-GM-CSF antibody of the invention, may for example, have a CDR3-FR4 that has the sequence R(Q/D)RFPYYFDYWGQGTLVTVSS (SEQ ID NO:23) and a CDR1 and/or CDR2 as shown in Figure 1.

15 [0058] In some embodiments, a  $V_H$  region of an antibody of the invention has a CDR3 that has a binding specificity determinant R(Q/D)RFPY (SEQ ID NO:22), a CDR2 from a human germline VH1 segment or a CDR1 from a human germline VH1. In some embodiments, both the CDR1 and CDR2 are from human germline VH1 segments.

### III. Light chains

20 [0059] A light chain of an anti-GM-CSF antibody of the invention comprises at light-chain V-region that comprises the following elements:

- 1) human light-chain V-segment sequences comprising FR1-CDR1-FR2-CDR2-FR3
- 2) a CDRL3 region comprising the sequence FNK or FNR, *e.g.*, QQFNRSPLT (SEQ ID NO:28) or QQFNKSPLT (SEQ ID NO:18).
- 25 3) a FR4 contributed by a human germ-line J-gene segment.

The  $V_L$  region comprises either a  $V_{\lambda}$  or a  $V_{\kappa}$  V-segment. An example of a  $V_{\kappa}$  sequence that supports binding in combination with a complementary  $V_H$ -region is provided in Figure 1.

30 [0060] The  $V_L$  region CDR3 sequence comprises a J-segment derived sequence. In typical embodiments, the J-segment sequences in CDRL3 are from the same J-segment used for FR4. Thus, the sequence in some embodiments may differ by not more than 2 amino acids from human kappa germ-line V-segment and J-segment sequences. In some embodiments, the CDRL3-FR4

region comprises the BSD and the complete human JK4 germline gene segment. Exemplary CDRL3-FR4 combinations for kappa chains are shown below in which the minimal essential binding specificity determinant is shown in bold and JK4 sequences are underlined:

CDR3

5    QQ**FNR**SPLTFGGGTKEIK    (SEQ ID NO:29)  
       QQ**FNK**SPLTFGGGTKEIK    (SEQ ID NO:30)

[0061] The Vkappa segments are typically of the VKIII sub-class. In some embodiments, the segments have at least 80% sequence identity to a human germline VKIII subclass, *e.g.*, 10 at least 80% identity to the human germ-line VKIIIA27 sequence. In some embodiments, the Vkappa segment may differ by not more than 18 residues from VKIIIA27. In other embodiments, the V<sub>L</sub> region V-segment of an antibody of the invention has at least 85% identity, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the human kappa V-segment sequence of a V<sub>L</sub> region shown in Figure 1, for 15 example, the V-segment sequence of VK#1, VK#2, VK#3, or VK#4.

[0062] In some embodiments, the V-segment of the V<sub>L</sub> region has a CDR1 and/or CDR2 as shown in Figure 1. For example, an antibody of the invention may have a CDR1 sequence of RASQSVGTNVA (SEQ ID NO:31) or RASQSIGSNLA (SEQ ID NO:32); or a CDR2 sequence STSSRAT (SEQ ID NO:33).

20 [0063] In particular embodiments, an anti-GM-CSF antibody of the invention may have a CDR1 and a CDR2 in a combination as shown in one of the V-segments of the V<sub>L</sub> regions set forth in Figure 1 and a CDR3 sequence that comprises FNK or FNR, *e.g.*, the CDR3 may be QQFNKSPLT (SEQ ID NO:18) or QQFNRSP~~L~~T (SEQ ID NO:28). In some embodiments, such a GM-CSF antibody may 25 comprise an FR4 region that is FGGGTKEIK (SEQ ID NO:34). Thus, an anti-GM-CSF antibody of the invention, can comprise, *e.g.*, both the CDR1 and CDR2 from one of the V<sub>L</sub> regions shown in Figure 1 and a CDR3-FR4 region that is FGGGTKEIK (SEQ ID NO:34).

#### IV. Preparation of GM-CSF antibodies

[0064] An antibody of the invention may comprise any of the V<sub>H</sub> regions VH#1, VH#2, VH#3, VH#4, or VH#5 as shown in Figure 1. In some embodiment, an antibody of the 30 invention may comprise any of the V<sub>L</sub> regions VK#1, VK#2, VK#3, or VK#4 as shown in Figure 1. In some embodiments, the antibody has a V<sub>H</sub> region VH#1, VH#2, VH#3, VH#4, or VH#5 as shown in Figure 1; and a V<sub>L</sub> region VK#1, VK#2, VK#3, or VK#4 as shown in Figure 1.

[0065] An antibody may be tested to confirm that the antibody retains the activity of antagonizing GM-CSF activity. The antagonist activity can be determined using any number of endpoints, including proliferation assays. Anti-GM-CSF antibodies may be evaluated using any number of assays that assess GM-CSF function. For example, cell-based assays for GM-CSF receptor signaling, such as assays which determine the rate of proliferation of a GM-CSF-dependent cell line in response to a limiting amount of GM-CSF, are conveniently used. The human TF-1 cell line is suitable for use in such an assay. See, Krinner *et al.*, (2007) *Mol. Immunol.* An antibody that is administered to treat a disease for which it is desirable to inhibit GM-CSF preferably retains at least about 50%, or at least about 75%, 80%, 90%, 95%, or 100%, of the antagonist activity of the antibody chimeric c19/2, *e.g.*, 5 WO03/068920, which has the variable regions of the mouse monoclonal antibody LMM102 and the CDRs, as defined by Kabat:

CDRH1	DYNIIH (SEQ ID NO:35)
CDRH2	YIAPYSGGTGYNQEFKN (SEQ ID NO:36)
CDRH3	RDRFPYYFDY (SEQ ID NO:16)
CDRL1	KASQNVGSNVA (SEQ ID NO:37)
CDRL2	SASYRSG (SEQ ID NO:38)
CDRL3	QQFNRSPLT (SEQ ID NO:28).

[0066] A high-affinity antibody may be identified using well known assays to determine binding activity and affinity. Such techniques include ELISA assays as well as binding 15 determinations that employ surface plasmon resonance or interferometry. For example, affinities can be determined by biolayer interferometry using a ForteBio (Mountain View, CA) Octet biosensor. An antibody of the invention typically binds with similar affinity to both glycosylated and non-glycosylated forms of GM-CSF.

[0067] Antibodies of the invention compete with c19/2 for binding to GM-CSF. The 25 ability of an antibody described herein to block or compete with c19/2 for binding to GM-CSF indicates that the antibody binds to the same epitope c19/2 or to an epitope that is close to, *e.g.*, overlapping, with the epitope that is bound by c19/2. In other embodiments an antibody described herein, *e.g.*, an antibody comprising a V<sub>H</sub> and V<sub>L</sub> region combination as shown in the table provided in Figure 1, can be used as a reference antibody for assessing 30 whether another antibody competes for binding to GM-CSF. A test antibody is considered to competitively inhibit binding of a reference antibody, if binding of the reference antibody to the antigen is reduced by at least 30%, usually at least about 40%, 50%, 60% or 75%, and often by at least about 90%, in the presence of the test antibody. Many assays can be employed to assess binding, including ELISA, as well as other assays, such as immunoblots.

[0068] Methods for the isolation of antibodies with V-region sequences close to human germ-line sequences have previously been described (US patent application publication nos. 20050255552 and 20060134098). Antibody libraries may be expressed in a suitable host cell including mammalian cells, yeast cells or prokaryotic cells. For expression in some cell systems, a signal peptide can be introduced at the N-terminus to direct secretion to the extracellular medium. Antibodies may be secreted from bacterial cells such as *E. coli* with or without a signal peptide. Methods for signal-less secretion of antibody fragments from *E. coli* are described in US patent application 20070020685.

[0069] To generate a GM-CSF-binding antibody, one of the  $V_H$ -regions of the invention, e.g., shown in Figure 1, is combined with one of the  $V_L$ -regions of the invention, e.g., shown in Figure 1, and expressed in any of a number of formats in a suitable expression system. Thus the antibody may be expressed as a scFv, Fab, Fab' (containing an immunoglobulin hinge sequence),  $F(ab')_2$ , (formed by di-sulfide bond formation between the hinge sequences of two Fab' molecules), whole immunoglobulin or truncated immunoglobulin or as a fusion protein in a prokaryotic or eukaryotic host cell, either inside the host cell or by secretion. A methionine residue may optionally be present at the N-terminus, for example, in polypeptides produced in signal-less expression systems. Each of the  $V_H$ -regions described herein may be paired with each of the  $V_L$  regions to generate an anti-GM-CSF antibody. Exemplary combinations of heavy and light chains are shown in the table in Figure 1.

[0070] The antibodies of the invention inhibit GM-CSF receptor activation, e.g., by inhibiting GM-CSF binding to the receptor, and exhibit high affinity binding to GM-CSF, e.g., 500 pM. In some embodiments, the antibody has a dissociation constant of about  $10^{-4}$  per sec or less. Not to be bound by theory, an antibody with a slower dissociation constant provides improved therapeutic benefit. For example, an antibody of the invention that has a three-fold slower off-rate than c19/2, produced a 10-fold more potent GM-CSF neutralizing activity, e.g., in a cell-based assay such as IL-8 production (see, e.g., Example 2).

[0071] Antibodies may be produced using any number of expression systems, including both prokaryotic and eukaryotic expression systems. In some embodiments, the expression system is a mammalian cell expression, such as a CHO cell expression system. Many such systems are widely available from commercial suppliers. In embodiments in which an antibody comprises both a  $V_H$  and  $V_L$  region, the  $V_H$  and  $V_L$  regions may be expressed using a single vector, e.g., in a discistronic expression unit, or under the control of different

promoters. In other embodiments, the  $V_H$  and  $V_L$  region may be expressed using separate vectors. A  $V_H$  or  $V_L$  region as described herein may optionally comprise a methionine at the N-terminus.

**[0072]** An antibody of the invention may be produced in any number of formats, including as a Fab, a Fab', a F(ab')<sub>2</sub>, a scFv, or a dAB. An antibody of the invention can also include a human constant region. The constant region of the light chain may be a human kappa or lambda constant region. The heavy chain constant region is often a gamma chain constant region, for example, a gamma-1, gamma-2, gamma-3, or gamma-4 constant region. In other embodiments, the antibody may be an IgA.

10 **[0073]** In some embodiments of the invention, the antibody  $V_L$  region, *e.g.*, VK#1, VK#2, VK#3, or VK#4 of Figure 1, is combined with a human kappa constant region (*e.g.*, SEQ ID NO:10) to form the complete light-chain.

15 **[0074]** In some embodiments of the invention, the  $V_H$  region is combined a human gamma-1 constant region. Any suitable gamma-1 f allotype can be chosen, such as the f-allotype. Thus, in some embodiments, the antibody is an IgG having an f-allotype constant region, *e.g.*, SEQ ID NO:11, that has a  $V_H$  selected from VH#1, VH#2, VH#3, VH#4, or VH#5 (Figure 1). In some embodiments, the antibody has a  $V_L$  selected from VK#1, VK#2, VK#3, or VK#4 (Figure 1.) In particular embodiments, the antibody has a kappa constant region as set forth in SEQ ID NO:10, and a heavy chain constant region as set forth in SEQ ID NO:11, where the heavy and light chain variable regions comprise one of the following combinations from the sequences set forth in Figure 1: a) VH#2, VK#3; b) VH#1, VK#3; c) VH#3, VK#1; d) VH#3, VL#3; e) VH#4, VK#4; f) VH#4, VK#2; g) VH#5, VK#1; h) VH#5, VK#2; i) VH#3, VK#4; or j) VH#3, VL#3).

20 **[0075]** In some embodiments, *e.g.*, where the antibody is a fragment, the antibody can be conjugated to another molecule, *e.g.*, polyethylene glycol (PEGylation) or serum albumin, to provide an extended half-life *in vivo*. Examples of PEGylation of antibody fragments are provided in Knight *et al.* *Platelets* 15:409, 2004 (for abciximab); Pedley *et al.*, *Br. J. Cancer* 70:1126, 1994 (for an anti-CEA antibody); Chapman *et al.*, *Nature Biotech.* 17:780, 1999; and Humphreys, *et al.*, *Protein Eng. Des.* 20: 227,2007).

30 **[0076]** In some embodiments, the antibodies of the invention are in the form of a Fab' fragment. A full-length light chain is generated by fusion of a  $V_L$ -region to human kappa or lambda constant region. Either constant region may be used for any light chain; however, in

typical embodiments, a kappa constant region is used in combination with a  $V\kappa$  variable region and a lambda constant region is used with a  $V\lambda$  variable region.

[0077] The heavy chain of the Fab' is a Fd' fragment generated by fusion of a  $V_H$ -region of the invention to human heavy chain constant region sequences, the first constant (CH1) 5 domain and hinge region. The heavy chain constant region sequences can be from any of the immunoglobulin classes, but is often from an IgG, and may be from an IgG1, IgG2, IgG3 or IgG4. The Fab' antibodies of the invention may also be hybrid sequences, *e.g.*, a hinge sequence may be from one immunoglobulin sub-class and the CH1 domain may be from a different sub-class.

10 **V. Administration of anti-GM-CSF antibodies for the treatment of diseases in which GM-CSF is a target.**

[0078] The invention also provides methods of treating a patient that has a disease involving GM-CSF in which it is desirable to inhibit GM-CSF activity, *i.e.*, in which GM-CSF is a therapeutic target. In some embodiments, such a patient has a chronic inflammatory 15 disease, *e.g.*, arthritis, *e.g.*, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and other inflammatory diseases of the joint; inflammatory bowel diseases, *e.g.*, ulcerative colitis, Crohn's disease, Barrett's syndrome, ileitis, enteritis, and gluten-sensitive enteropathy; inflammatory disorders of the respiratory system, such as asthma, adult respiratory distress syndrome, allergic rhinitis, silicosis, chronic obstructive 20 pulmonary disease, hypersensitivity lung diseases, bronchiectasis; inflammatory diseases of the skin, including psoriasis, scleroderma, and inflammatory dermatoses such as eczema, atopic dermatitis, urticaria, and pruritis; disorders involving inflammation of the central and peripheral nervous system, including multiple sclerosis, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, chronic inflammatory demyelinating 25 polyneuropathy, and neurodegenerative diseases such as Alzheimer's disease. Various other inflammatory diseases can be treated using the methods of the invention. These include systemic lupus erythematosus, immune-mediated renal disease, *e.g.*, glomerulonephritis, and spondyloarthropathies; and diseases with an undesirable chronic inflammatory component such as systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's syndrome, 30 vasculitis, sarcoidosis, thyroiditis, gout, otitis, conjunctivitis, sinusitis, sarcoidosis, Behcet's syndrome, hepatobiliary diseases such as hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis. In some embodiments, the patient has inflammation

following injury to the cardiovascular system. Various other inflammatory diseases include tuberculosis and chronic cholecystitis. Additional chronic inflammatory diseases are described, e.g., in Harrison's Principles of Internal Medicine, 12th Edition, Wilson, et al., eds., McGraw-Hill, Inc.). In some embodiments, a patient treated with an antibody has a 5 cancer in which GM-CSF contributes to tumor or cancer cell growth, e.g., acute myeloid leukemia. In some embodiments, a patient treated with an antibody of the invention has, or is at risk of heart failure, e.g., due to ischemic injury to the cardiovascular system such as ischemic heart disease, stroke, and atherosclerosis. In some embodiments, a patient treated with an antibody of the invention has asthma. In some embodiments, a patient treated with 10 an antibody of the invention has Alzheimer's disease. In some embodiments, a patient treated with an antibody of the invention has osteopenia, e.g., osteoporosis. In some embodiments, a patient treated with an antibody of the invention has thrombocytopenia purpura. In some embodiments, the patient has Type I or Type II diabetes. In some 15 embodiments, a patient may have more than one disease in which GM-CSF is a therapeutic target, e.g., a patient may have rheumatoid arthritis and heart failure, or osteoporosis and rheumatoid arthritis, etc.

**[0079]** The methods of the invention comprise administering an anti-GM-CSF antibody as a pharmaceutical composition to a patient in a therapeutically effective amount using a dosing regimen suitable for treatment of the disease. The composition can be formulated for 20 use in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can also be included in the compositions for proper formulation. Suitable formulations for use in the present invention are found in *Remington: The Science and Practice of Pharmacy*, 21st Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.

**[0080]** The anti-GM-CSF antibody is provided in a solution suitable for injection into the 25 patient such as a sterile isotonic aqueous solution for injection. The antibody is dissolved or suspended at a suitable concentration in an acceptable carrier. In some embodiments the carrier is aqueous, e.g., water, saline, phosphate buffered saline, and the like. The compositions may contain auxillary pharmaceutical substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, 30 and the like.

**[0081]** The pharmaceutical compositions of the invention are administered to a patient, e.g., a patient that has osteopenia, asthma, rheumatoid arthritis, psoriatic arthritis, ankylosing

spondylitis, juvenile idiopathic arthritic, polymyositis, systemic lupus erythermatosus, heart failure, cardiac damage, *e.g.*, following a heart attack, thrombocytopenia purpura, or diabetes, in an amount sufficient to cure or at least partially arrest the disease or symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a 5 "therapeutically effective dose." A therapeutically effective dose is determined by monitoring a patient's response to therapy. Typical benchmarks indicative of a therapeutically effective dose include amelioration of symptoms of the disease in the patient. Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health, including other factors such as age, weight, gender, 10 administration route, etc. Single or multiple administrations of the antibody may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the methods provide a sufficient quantity of anti-GM-CSF antibody to effectively treat the patient.

15 [0082] The antibody may be administered alone, or in combination with other therapies to treat the disease of interest.

20 [0083] The antibody can be administered by injection or infusion through any suitable route including but not limited to intravenous, sub-cutaneous, intramuscular or intraperitoneal routes. In some embodiments, the antibody may be administered by insufflation. In an exemplary embodiment, the antibody may be stored at 10 mg/ml in sterile isotonic aqueous saline solution for injection at 4°C and is diluted in either 100 ml or 200 ml 0.9% sodium chloride for injection prior to administration to the patient. The antibody is administered by intravenous infusion over the course of 1 hour at a dose of between 0.2 and 10 mg/kg. In other embodiments, the antibody is administered by intravenous infusion over a period of between 15 minutes and 2 hours. In still other embodiments, the administration procedure is 25 via sub-cutaneous bolus injection.

30 [0084] The dose of antibody is chosen in order to provide effective therapy for the patient and is in the range of less than 0.1 mg/kg body weight to about 25 mg/kg body weight or in the range 1 mg – 2 g per patient. Preferably the dose is in the range 1 – 10 mg/kg or approximately 50 mg – 1000 mg / patient. The dose may be repeated at an appropriate frequency which may be in the range once per day to once every three months, depending on the pharmacokinetics of the antibody (*e.g.*, half-life of the antibody in the circulation) and the pharmacodynamic response (*e.g.*, the duration of the therapeutic effect of the antibody). In

some embodiments, the *in vivo* half-life of between about 7 and about 25 days and antibody dosing is repeated between once per week and once every 3 months. In other embodiments, the antibody is administered approximately once per month.

5 [0085] A V<sub>H</sub> region and/or V<sub>L</sub> region of the invention may also be used for diagnostic purposes. For example, the V<sub>H</sub> and/or V<sub>L</sub> region may be used for clinical analysis, such as detection of GM-CSF levels in a patient. A V<sub>H</sub> or V<sub>L</sub> region of the invention may also be used, *e.g.*, to produce anti-Id antibodies.

## EXAMPLES

### Example 1. Identification of engineered human anti-GM-CSF V regions.

10 [0086] Humaneering was performed as described in US patent application publication no. 20050255552. Epitope-focused libraries were constructed from human V-segment library sequences linked to a CDR3-FR4 region containing BSD sequences in CDRH3 and CDRL3 together with human germ-line J-segment sequences. For the heavy chain, human germ-line JH4 sequence was used and for the light chain, human germ-line JK4 sequence was used.

15 [0087] Full-length Humaneered V-regions from a Vh1-restricted library were selected that supported binding to recombinant human GM-CSF. The “full-length” V-kappa library was used as a base for construction of “cassette” libraries as described in US patent application publication no. 20060134098, in which only part of the murine c19/2 V-segment was initially replaced by a library of human sequences. Two types of cassettes were constructed.

20 Cassettes for the V-kappa chains were made by bridge PCR with overlapping common sequences within the framework 2 region. In this way “front-end” and “middle” human cassette libraries were constructed for the human V-kappa III isotype. Human V-kappa III cassettes which supported binding to GM-CSF were identified by colony-lift binding assay and ranked according to affinity in ELISA. The V-kappa human “front-end” and “middle” 25 cassettes were fused together by bridge PCR to reconstruct a fully human V-kappa region that supported GM-CSF binding activity. The Humaneered Fabs thus consist of Humaneered V-heavy and V-kappa regions that support binding to human GM-CSF.

[0088] Binding activity was determined by surface plasmon resonance (spr) analysis. Biotinylated GM-CSF was captured on a streptavidin-coated CM5 biosensor chip. 30 Humaneered Fab fragments expressed from *E. coli* were diluted to a starting concentration of 30 nM in 10 mM HEPES, 150 mM NaCl, 0.1 mg/ml BSA and 0.005% P20 at pH 7.4. Each

Fab was diluted 4 times using a 3-fold dilution series and each concentration was tested twice at 37°C to determine the binding kinetics with the different density antigen surfaces. The data from all three surfaces were fit globally to extract the dissociation constants.

Exemplary humaneered anti-GM-CSF V regions are shown in Figure 1.

5 Example 2. Evaluation of a humaneered GM-CSF antibody

[0089] This example evaluates the binding activity and biological potency of a humaneered anti-GM-CSF antibody in a cell-based assay in comparison to a chimeric IgG1k antibody (Ab2) having variable regions from the mouse antibody LMM102 (Nice *et al.*, *Growth Factors* 3:159, 1990). Ab1 is a humaneered IgG1k antibody against GM-CSF having 10 identical constant regions to Ab2.

*Surface plasmon resonance analysis of binding of human GM-CSF to Ab1 and Ab2*

[0090] Surface Plasmon resonance analysis was used to compare binding kinetics and monovalent affinities for the interaction of Ab1 and Ab2 with glycosylated human GM-CSF using a Biacore 3000 instrument. Ab1 or Ab2 was captured onto the Biacore chip surface 15 using polyclonal anti-human F(ab')2. Glycosylated recombinant human GM-CSF expressed from human 293 cells was used as the analyte. Kinetic constants were determined in 2 independent experiments (see Figure 2 and Table 1). The results show that GM-CSF bound to Ab2 and Ab1 with comparable monovalent affinity in this experiment. However, Ab1 had a two-fold slower “on-rate” than Ab2, but an “off-rate” that was approximately three-fold 20 slower.

Table 1: Kinetic constants at 37°C determined from the surface plasmon resonance analysis in Figure 2; association constant ( $k_a$ ), dissociation constant ( $k_d$ ) and calculated affinity (KD) are shown.

	$k_a$ ( $M^{-1}s^{-1}$ )	$k_d$ ( $s^{-1}$ )	KD (pM)
Ab2	$7.20 \times 10^5$	$2.2 \times 10^{-5}$	30.5
Ab1	$2.86 \times 10^5$	$7.20 \times 10^{-6}$	25.1

[0091] GM-CSF is naturally glycosylated at both N-linked and O-linked glycosylation sites 25 although glycosylation is not required for biological activity. In order to determine whether GM-CSF glycosylation affects the binding of Ab1 or Ab2, the antibodies were compared in an ELISA using recombinant GM-CSF from two different sources; GM-CSF expressed in *E. coli* (non-glycosylated) and GM-CSF expressed from human 293 cells (glycosylated). The

results in Figure 3 and Table 2 showed that both antibodies bound glycosylated and non-glycosylated GM-CSF with equivalent activities. The two antibodies also demonstrated comparable EC<sub>50</sub> values in this assay.

5 Table 2. Summary of EC<sub>50</sub> for binding of Ab2 and Ab1 to human GM-CSF from two different sources determined by ELISA. Binding to recombinant GM-CSF from human 293 cells (glycosylated) or from *E. coli* (non-glycosylated) was determined from two independent experiments. Experiment 1 is shown in Figure 5.

	Non-glycosylated (exp 1)	Non-glycosylated (exp 2)	Glycosylated (exp 1)
Ab2	400 pM	433 pM	387pM
Ab1	373 pM	440 pM	413pM

10 [0092] Ab1 is a humanized antibody that was derived from the mouse variable regions present in Ab2. Ab1 was tested for overlapping epitope specificity (Ab2) by competition ELISA.

[0093] Biotinylated Ab2 was prepared using known techniques. Biotinylation did not affect binding of Ab2 to GM-CSF as determined by ELISA. In the assay, Ab2 or Ab1 was 15 added in varying concentrations with a fixed amount of biotinylated Ab2. Detection of biotinylated Ab2 was assayed in the presence of unlabeled Ab or Ab1 competitor (Figure 4). Both Ab1 and Ab2 competed with biotinylated Ab2 for binding to GM-CSF, thus indicating binding to the same epitope. Ab1 competed more effectively for binding to GM-CSF than Ab2, consistent with the slower dissociation kinetics for Ab1 when compared with Ab2 by 20 surface plasmon resonance analysis.

*Neutralization of GM-CSF activity by Ab1 and Ab2*

[0094] A cell based assay for neutralization of GM-CSF activity was employed to evaluate biological potency. The assay measures IL-8 secretion from U937 cells induced with GM-CSF. IL-8 secreted into the culture supernatant is determined by ELISA after 16 hours 25 induction with 0.5 ng/ml *E. coli*-derived GM-CSF.

[0095] A comparison of the neutralizing activity of Ab1 and Ab2 in this assay is shown in a representative assay in Figure 5. In three independent experiments, Ab1 inhibited GM-CSF activity more effectively than Ab2 when comparing IC<sub>50</sub> (Table 3).

Table 3. Comparison of IC<sub>50</sub> for inhibition of GM-CSF induced IL-8 expression. Data from three independent experiments shown in Figure 5 and mean IC<sub>50</sub> are expressed in ng/ml and nM.

Experiment	Ab2 (ng/ml)	Ab2 (nM)	Ab1 (ng/ml)	Ab1 (nM)
A	363	2.4	31.3	0.21
B	514	3.4	92.5	0.62
C	343	2.2	20.7	0.14
<b>Mean</b>	<b>407</b>	<b>2.7</b>	<b>48.2</b>	<b>0.32</b>

*Summary*

5 The humaneered Ab1 bound to GM-CSF with a calculated equilibrium binding constant (KD) of 25 pM. Ab2 bound to GM-CSF with a KD of 30.5 pM. Ab2 showed a two-fold higher association constant (k<sub>a</sub>) than Ab1 for GM-CSF while Ab1 showed three-fold slower dissociation kinetics (k<sub>d</sub>) than Ab2. Ab2 and Ab1 showed similar binding activity for glycosylated and non-glycosylated GM-CSF in an antigen-binding ELISA. A competition ELISA confirmed that both 10 antibodies competed for the same epitope; Ab1 showed higher competitive binding activity than Ab2. In addition, Ab1 showed higher GM-CSF neutralization activity than Ab2 in a GM-CSF-induced IL-8 induction assay.

15 [0096] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the scope of the invention.

SEQUENCE LISTING

20 This description contains a sequence listing in electronic form in ASCII text format. A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office. SEQ ID NO:39 is reproduced below.

Arg Ala Ser Gln Ser Xaa Gly Xaa Asn Xaa Ala

25 1 5 10

**Exemplary V<sub>H</sub> region sequences of anti-GM-CSF antibodies of the invention:****SEQ ID NO:1 (VH#1, Figure 1)**

QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPN  
 SGGTNYAQKFQGRVTMTRDTSISTAYMELSRLSDDTAVYYCVRDRFPYYFDYW  
 5 GQGTLTVSS

**SEQ ID NO:2 (VH#2, Figure 1)**

QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAG  
 NGNTKYSQKFQGRVAITRDTASTAYMELSSLRSEDTAVYYCARRDRFPYYFDYW  
 10 QGTLTVSS

**SEQ ID NO:3 (VH#3, Figure 1)**

QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAG  
 NGNTKYSQKFQGRVAITRDTASTAYMELSSLRSEDTAVYYCARRQRFPYYFDYW  
 15 QGTLTVSS

**SEQ ID NO:4 (VH#4, Figure 1)**

QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAG  
 NGNTKYSQKFQGRVAITRDTASTAYMELSSLRSEDTAVYYCVRDRFPYYFDYW  
 20 QGTLTVSS

**SEQ ID NO:5 (VH#5, Figure 1)**

QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAG  
 NGNTKYSQKFQGRVTITRDTASTAYMELSSLRSEDTAVYYCVRDRFPYYFDYW  
 25 QGTLTVSS

**Exemplary V<sub>L</sub> region sequences of anti-GM-CSF antibodies of the invention:****SEQ ID NO:6 (VK#1, Figure 1)**

EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIVYSTSSRATGI  
 30 TDRFSGSGSGTDFLTISRLEPEDFAVYYCQQFNRSPLTFGGGTKVEIK

**SEQ ID NO:7 (VK#2, Figure 1)**

EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGI  
TDRFSGSGSGTDFLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK

5

**SEQ ID NO:8 (VK#3, Figure 1)**

EIVLTQSPATLSVSPGERATLSCRASQSIGSNLAWYQQKPGQAPRVLIYSTSSRATGIT  
DRFSGSGSGTDFLTISRLEPEDFAVYYCQQFNRSPLTFGGGTKVEIK

10 **SEQ ID NO:9 (VK#4, Figure 1)**

EIVLTQSPATLSVSPGERATLSCRASQSIGSNLAWYQQKPGQAPRVLIYSTSSRATGIT  
DRFSGSGSGTDFLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK

15 **SEQ ID NO:10 Exemplary kappa constant region**

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT  
EQDSKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

**SEQ ID NO:11 Exemplary heavy chain constant region, f-allotype:**

20 ASTKGPSVFPLAPSSKSTSGGTAAALGCLVKDYFPEPVTVWSNSGALTSGVHTFPAVL  
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAP  
ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT  
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP  
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGS  
25 FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

WHAT IS CLAIMED IS:

1. An anti-GM-CSF antibody, comprising:
  - (a) a  $V_H$  region that comprises a CDR3 having the amino acid sequence RQRFPYYFDY (SEQ ID NO:15); a CDR1 having the amino acid sequence NYYIH (SEQ ID NO:25); and a CDR2 having the amino acid sequence WINAGNGNTKYSQKFQG (SEQ ID NO:27); and a  $V_L$  region that comprises a CDR3 having the amino acid sequence QQFNKSPLT (SEQ ID NO:18) or QQFNRSPLT (SEQ ID NO:28); a CDR1 having the amino acid sequence RASQSVGTNVA (SEQ ID NO:31) or RASQSIGSNLA (SEQ ID NO:32); and a CDR2 having the amino acid sequence STSSRAT (SEQ ID NO:33).
2. The antibody of claim 1, wherein the  $V_L$  region comprises a CDR3 having the amino acid sequence QQFNKSPLT (SEQ ID NO:18) or QQFNRSPLT (SEQ ID NO:28), a CDR1 having the amino acid sequence RASQSVGTNVA (SEQ ID NO:31), and a CDR2 having the amino acid sequence STSSRAT (SEQ ID NO:33).
3. The antibody of claim 1, wherein the  $V_L$  region comprises a CDR3 having the amino acid sequence QQFNKSPLT (SEQ ID NO:18), a CDR1 having the amino acid sequence RASQSVGTNVA (SEQ ID NO:31), and a CDR2 having the amino acid sequence STSSRAT (SEQ ID NO:33).
4. The antibody of claim 1, 2, or 3, wherein the  $V_H$  region FR4 amino acid sequence is WGQGTLTVSS.
5. The antibody of any one of claims 1 to 4, wherein the  $V_L$  region FR4 amino acid sequence is FGGGTKVEIK (SEQ ID NO:2).
6. The antibody of any one of claims 1 to 5, wherein the  $V$ -segment of the  $V_H$  region has the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
7. The antibody of any one of claims 1 to 5, wherein the  $V_H$  has the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

8. The antibody of any one of claims 1 to 7, wherein the V-segment of the V<sub>L</sub> region has the amino acid sequence of SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:9.
9. The antibody of any one of claims 1 to 7, wherein the V<sub>L</sub> region has the amino acid sequence of SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:9.
10. The antibody of claim 1, wherein the antibody has a heavy chain variable region sequence and a light chain variable region sequence selected from the group consisting of:
  - (a) the V<sub>H</sub> amino acid sequence of SEQ ID NO:3 and the V<sub>L</sub> amino acid sequence of SEQ ID NO:6;
  - (b) the V<sub>H</sub> amino acid sequence of SEQ ID NO:4 and the V<sub>L</sub> amino acid sequence of SEQ ID NO:9;
  - (c) the V<sub>H</sub> amino acid sequence of SEQ ID NO:4 and the V<sub>L</sub> amino acid sequence of SEQ ID NO:7; and
  - (d) the V<sub>H</sub> amino acid sequence of SEQ ID NO:5 and the V<sub>L</sub> amino acid sequence of SEQ ID NO:6.
11. The antibody of any one claims 1 to 10, wherein the antibody is an IgG.
12. The antibody of any one of claims 1 to 11, wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11.
13. The antibody of any one of claims 1 to 11, wherein the antibody comprises a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.
14. The antibody of any one of claims 1 to 11, wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11 and a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.
15. The antibody of claim 1, wherein the antibody has a heavy chain variable region amino acid sequence of SEQ ID NO:5 and a light chain variable region amino acid sequence of SEQ ID NO:7.

16. The antibody of claim 15, wherein the antibody is an IgG.
17. The antibody of claim 15 or 16, wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11.
18. The antibody of claim 15 or 16, wherein the antibody comprises a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.
19. The antibody of claim 15 or 16, wherein the antibody comprises a heavy chain constant region having the amino acid sequence set forth in SEQ ID NO:11 and a kappa light chain constant region having the amino acid sequence set forth in SEQ ID NO:10.
20. The antibody of any one of claims 1 to 19, wherein the  $V_H$  region or the  $V_L$  region, or both the  $V_H$  and  $V_L$  region amino acid sequences comprise a methionine at the N-terminus.
21. A pharmaceutical composition comprising an antibody as defined in any one of claims 1 to 20 and a physiologically acceptable carrier.
22. A pharmaceutical composition comprising an antibody of any one of claims 15 to 19 and a physiologically acceptable carrier.

## FIGURE 1

VH1 1-02	QVQLVQSGAEVKPGASVKVSKASGYTFTGYMHEWVRQAPGQLEWMGWINPNSGGTNYAQKFQGRVTMTRDTISI
VH#1	QVQLVQSGAEVKPGASVKVSKASGYTFTGYMHEWVRQAPGQLEWMGWINPNSGGTNYAQKFQGRVTMTRDTISI
VH1 1-03	QVQLVQSGAEVKPGASVKVSKASGYTFTSYAMHWRQAPGQLEWMGWINAGNGNTKYSQKFQGRVTITRDTISASTAYMELSLRSDDTTAVYCAR-----
VH#2	QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHWYRQAPGQLEWMGWINAGNGNTKYSQKFQGRVAITRDTISASTAYMELSLRSDDTTAVYCARREPFYYFDYWGQGTIVYSS
VH#3	QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHWYRQAPGQLEWMGWINAGNGNTKYSQKFQGRVAITRDTISASTAYMELSLRSDDTTAVYCARREPFYYFDYWGQGTIVYSS
VH#4	QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHWYRQAPGQLEWMGWINAGNGNTKYSQKFQGRVAITRDTISASTAYMELSLRSDDTTAVYCARREPFYYFDYWGQGTIVYSS
VH#5	QVQLVQSGAEVKPGASVKVSKASGYTFTNYIHWYRQAPGQLEWMGWINAGNGNTKYSQKFQGRVTITRDTISASTAYMELSLRSDDTTAVYCARREPFYYFDYWGQGTIVYSS
VKIII A27	EIVLTQSPGTLLSPGERATLSCRASQSVSSSYLANYQKPGQAPRLIYGAASSRATGIPDRSGSGTDFTLTISLEPEDFAVYCOQYGSPP-----
VK#1	EIVLTQSPATLVSPGERATLSCRASQSVGTN-VAWYQOKPGQAPRVLITYSTSSRATGITDRESGSGTDFTLTISLEPEDFAVYCOQFNKSPLTFGGGTKEIK
VK#2	EIVLTQSPATLVSPGERATLSCRASQSVGTN-VAWYQOKPGQAPRVLITYSTSSRATGITDRESGSGTDFTLTISLEPEDFAVYCOQFNKSPLTFGGGTKEIK
VK#3	EIVLTQSPATLVSPGERATLSCRASQSIGSN-LAWYQOKPGQAPRVLITYSTSSRATGITDRESGSGTDFTLTISLEPEDFAVYCOQFNRSPLTFGGGTKEIK
VK#4	EIVLTQSPATLVSPGERATLSCRASQSIGSN-LAWYQOKPGQAPRVLITYSTSSRATGITDRESGSGTDFTLTISLEPEDFAVYCOQFNKSPLTFGGGTKEIK

Fab	V <sub>h</sub>	V <sub>h</sub>	V <sub>k</sub>	Dissociation rate for binding to GM-CSF determined by surface plasmon resonance analysis (s <sup>-1</sup> )
FB42-8	#2	#3		1.36 x 10 <sup>-4</sup>
FB44-5	#1	#3		8.0 x 10 <sup>-5</sup>
FB77-2	#3	#1		5.57 x 10 <sup>-5</sup>
FB92-1	#4	#4		3.84 x 10 <sup>-5</sup>
FB94-1	#4	#2		3.12 x 10 <sup>-5</sup>
FB104-1	#5	#1		3.57 x 10 <sup>-5</sup>
FB106-1	#5	#2		5.4 x 10 <sup>-5</sup>

## FIGURE 2




Figure 3






Figure 4



## FIGURE 5



VH1 1-02                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVIMTRDTS I<sub>S</sub> T<sub>A</sub> T<sub>M</sub> E<sub>L</sub> S<sub>R</sub> L<sub>R</sub> S<sub>D</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>A</sub> R<sub>Y</sub> - - - - -

VH#1                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVIMTRDTS I<sub>S</sub> T<sub>A</sub> T<sub>M</sub> E<sub>L</sub> S<sub>R</sub> L<sub>R</sub> S<sub>D</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>V</sub> R<sub>R</sub> F<sub>P</sub> Y<sub>Y</sub> F<sub>D</sub> Y<sub>W</sub> Q<sub>G</sub> T<sub>L</sub> V<sub>T</sub> V<sub>S</sub>

VH1 1-03                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTYMHWVRQAPGQGLEWMGWINAGNGNTKYSQKFQGRVIT T<sub>R</sub> D<sub>T</sub> S<sub>A</sub> S<sub>T</sub> A<sub>M</sub> E<sub>L</sub> S<sub>R</sub> L<sub>R</sub> S<sub>E</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>A</sub> R<sub>Y</sub> - - - - -

VH#2                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTNYIHWVRQAPGQGLEWMGWINAGNGNTKYSQKFQGRVAIT R<sub>D</sub> T<sub>S</sub> A<sub>S</sub> T<sub>A</sub> M<sub>E</sub> L<sub>S</sub> L<sub>R</sub> S<sub>E</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>A</sub> R<sub>R</sub> F<sub>P</sub> Y<sub>Y</sub> F<sub>D</sub> Y<sub>W</sub> Q<sub>G</sub> T<sub>L</sub> V<sub>T</sub> V<sub>S</sub>

VH#3                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTNYIHWVRQAPGQGLEWMGWINAGNGNTKYSQKFQGRVAIT R<sub>D</sub> T<sub>S</sub> A<sub>S</sub> T<sub>A</sub> M<sub>E</sub> L<sub>S</sub> L<sub>R</sub> S<sub>E</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>A</sub> R<sub>R</sub> F<sub>P</sub> Y<sub>Y</sub> F<sub>D</sub> Y<sub>W</sub> Q<sub>G</sub> T<sub>L</sub> V<sub>T</sub> V<sub>S</sub>

VH#4                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTNYIHWVRQAPGQGLEWMGWINAGNGNTKYSQKFQGRVAIT R<sub>D</sub> T<sub>S</sub> A<sub>S</sub> T<sub>A</sub> M<sub>E</sub> L<sub>S</sub> L<sub>R</sub> S<sub>E</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>V</sub> R<sub>R</sub> F<sub>P</sub> Y<sub>Y</sub> F<sub>D</sub> Y<sub>W</sub> Q<sub>G</sub> T<sub>L</sub> V<sub>T</sub> V<sub>S</sub>

VH#5                    QVQLVQSGAEVKKPGASVKVKSCASGYTFTNYIHWVRQAPGQGLEWMGWINAGNGNTKYSQKFQGRVIT R<sub>D</sub> T<sub>S</sub> A<sub>S</sub> T<sub>A</sub> M<sub>E</sub> L<sub>S</sub> L<sub>R</sub> S<sub>E</sub> D<sub>T</sub> A<sub>V</sub> Y<sub>V</sub> C<sub>V</sub> R<sub>R</sub> F<sub>P</sub> Y<sub>Y</sub> F<sub>D</sub> Y<sub>W</sub> Q<sub>G</sub> T<sub>L</sub> V<sub>T</sub> V<sub>S</sub>

VKIII A27                    EIVLTQSPGTLSSLPGCERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGS<sub>S</sub>P - - - - -

VK#1                    EIVLTQSPATLSSVSPGERATLSCRASQSVGTN-WAVYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNRSPLTFGGGTKV<sub>E</sub>IK

VK#2                    EIVLTQSPATLSSVSPGERATLSCRASQSVGTN-WAVYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKV<sub>E</sub>IK

VK#3                    EIVLTQSPATLSSVSPGERATLSCRASQSGISN-LAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNRSPLTFGGGTKV<sub>E</sub>IK

VK#4                    EIVLTQSPATLSSVSPGERATLSCRASQSGISN-LAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKV<sub>E</sub>IK

Fab	Vh	Vk	Dissociation rate for binding to GM-CSF determined by surface plasmon resonance analysis (s <sup>-1</sup> )
FB42-8	#2	#3	$1.36 \times 10^{-4}$
FB44-5	#1	#3	$8.0 \times 10^{-5}$
FB77-2	#3	#1	$5.57 \times 10^{-5}$
FB92-1	#4	#4	$3.84 \times 10^{-5}$
FB94-1	#4	#2	$3.12 \times 10^{-5}$
FB104-1	#5	#1	$3.57 \times 10^{-5}$
FB106-1	#5	#2	$5.4 \times 10^{-5}$